LVOX yields 53.62% · ABBV yields 3.06%● Live data
📍 LVOX pulled ahead of the other in Year 1
Combined, LVOX + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LVOX + ABBV for your $10,000?
LiveVox, Inc. develops and provides cloud contact center software for businesses. Its products include Four Clouds, an outbound voice solution that enables to manage regulatory requirements with the option of three manual and one automated outbound dialing system; bundles, including two-way messaging, outbound campaigns and compliance, speech analytics, inbound contact center, and cloud interactive voice response (IVR) solutions; inbound voice solutions, which comprise automatic call distributor, IVR, and wallboards; and blended omnichannel solutions, such as voice, email, SMS, virtual agents, and webchat. The company also offers CRM, which leverages unified customer profiles to create, facilitate, and manages digital engagement; Workforce Optimization, that helps contact centers to measure and manage agent workforce; and SpeechIQ, an AI-driven speech analytics solution to promote compliance, productivity, and quality in contact centers. It serves financial services, teleservices, healthcare, telecom, customer care, BPO, and collection industries. The company has a strategic partnership with Telarus. LiveVox, Inc. was formerly known as Tools For Health, Inc. and changed its name to LiveVox, Inc. in June 2006. The company was incorporated in 1998 and is based in San Francisco, California. LiveVox, Inc. has additional locations in Atlanta, Georgia; Bengaluru, India; Denver, Colorado; Medellin, Colombia; New York, New York; St. Louis, Missouri; and Columbus, Ohio.
Full LVOX Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.